Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin’s lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Adicet Bio, Inc. (ACET)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
2 days ago | Zacks Investment Research
2 days ago | GlobeNewsWire
a week ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | GlobeNewsWire
2 months ago | Zacks Investment Research
3 months ago | GlobeNewsWire
4 months ago | GlobeNewsWire
5 months ago | GlobeNewsWire